The Nomination Committee at Probi AB proposes new Board members

This information was submitted for disclosure on 14 February 2017 at 08.15 (cet).

The Nomination Committee of Probi AB proposes to the AGM 2017 the election of Anna Malm Bernsten, Charlotte Hansson and Scott Bush as new members of the Board.

Furthermore, the Nomination Committee proposes the re-election of the Chairman of the Board Jean-Yves Parisot, as well as the Board members Jan Nilsson and Jonny Olsson.

Eva Redhe and Benedicte Fossum have declined re-election. Jörn Andreas has stepped down from the Board with immediate effect as he will take up the position of CFO at Probi on 1 March 2017, which has been previously communicated by the company.

“I would like to take this opportunity to express our thanks to Eva Redhe and Benedicte Fossum for their efforts and contribution to the fantastic growth and development of Probi during the many years they have served as board members.”, says Jean-Yves Parisot, Chairman of the Board.

Anna Malm Bernsten runs a consultancy business in the area of international business development, strategy, management and brand management issues. Anna has long and in-depth experience of Life Science including as President and CEO at Carmeda AB, as well as having held senior positions at Pharmacia, ASSA ABLOY AB and GE Healthcare. She has extensive experience of Board work, including as Chairman of the Board of Medivir and Board member of Cellavision AB, Arcam AB and Neurovive AB. Up until year-end 2016, Anna was Chairman of Oatly AB. She has a Masters degree in chemical engineering from the Royal Institute of Technology in Stockholm.

Charlotte Hansson is CEO of MTD; Morgontidig Distribution KB. Charlotte has extensive experience of Board work in listed and state-owned companies, including B&B Tools AB, BE Group AB and Orio AB. Charlotte has more than 20 years’ commercial experience of Transport/Logistics as well as from the Life Science sector and has held a number of leading positions, including that of CEO for Jetpak Sweden. Charlotte has a Bachelor of Science in Biochemistry from Copenhagen University and holds a diploma in marketing from IHM. 

Scott Bush has more than 20 years’ experience in leading positions in the probiotic industry, serving most recently as Global Director in the probiotics segment at DuPont. Scott has also held leading, global positions at Danisco and Rhodia. Scott, who is American and resident in the US, is a Board member of the International Probiotics Association and runs his own consultancy company through Probiotic Consulting LLC. Scott has a Bachelor of Science in food science, and an MBA, Finance from the University of Wisconsin.

The Nomination Committee has conducted an assessment of the proposed Board to verify that it is appropriately composed and fulfils the requirements that can be made of the Board based on the company’s current and future situation. The Nomination Committee is of the opinion that the Board members, based on their experiences and personal attributes, possess the skills and knowledge required to contribute to continued profitable growth and share performance at Probi.

Other proposals from the Nomination Committee will be presented in the notice of the Annual General Meeting, which will be held in Lund on Thursday, 4 May 2017 at 3:00 p.m. at the Elite Hotel, Ideon Gateway, Scheelevägen 27, Lund, Sweden.

FOR FURTHER INFORMATION, CONTACT:
Jannis Kitsakis, 4e AP-fonden, member of the Nomination Committee, jannis.kitsakis@ap4.se , tel: +46 706 03 80 23

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2016, Probi generated sales of MSEK 444. Probi’s shares are listed on Nasdaq Stockholm, Mid Cap. Probi has about 4,700 shareholders. For more information, please visit www.probi.se.

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links